17 patents currently held
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2027. from the record
Of the 6 now held by other companies, 5 name Baylor College of Medicine as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Jun 2027
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2034 · High confidence
Also notable
Ends Aug 2030 · High confidence
Also notable
Ends Jun 2027 · High confidence
Also notable
Ends Apr 2032 · High confidence
Also notable
Ends Dec 2032 · Medium confidence
Closed System Device and Methods for Gas Permeable Cell Culture Process
US 9,840,692
The most cited patent in this portfolio, cited by 107 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2034.
Generation of CTL Lines with Specificity Against Multiple Tumor Antigens or Multiple Viruses
US 9,963,677
Cited by 33 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Cell Culture Methods and Devices Utilizing Gas Permeable Materials
US 8,697,443
Cited by 59 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Methods of Growing Tumor Infiltrating Lymphocytes in Gas-Permeable Containers
US 11,401,503
Granted 2022. Computed term ends 2032.
Process for T Cell Expansion
US 11,963,979
A family of 5 related applications built on the 2024 grant. Too new for citation comparison; protection runs to 2032.
Formerly held, still cited
Notable
Ends Dec 2030 · High confidence
The most cited patent in this portfolio, cited by 262 later US patents, top 1% of utility patents granted in 2015 in our data. Protection runs to 2030.
now held by Baylor College of Medicine
Also notable
Ends Aug 2030 · High confidence
Cited by 29 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Baylor College of Medicine
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 21, 2027The maintenance fee for Methods of Cell Culture for Adoptive Cell Therapy (US 11,821,002) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 2 fees due Jul 14 to 16, 2027 · next Jul 14
- 1 fee due Sep 10, 2027The maintenance fee for Methods of Genetically Modifying Animal Cells (US 10,584,354) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Process for T Cell Expansion (US 11,963,979) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Gas Permeable Cell Culture Device and Method of Use | 13 in force | to May 2036 |
| Process for T Cell Expansion | 1 in force | to Dec 2032 |
| Methods of Growing Tumor Infiltrating Lymphocytes in Gas-Permeable Containers | 1 in force | to Apr 2032 |
| Generation of CTL Lines with Specificity Against Multiple Tumor Antigens or Multiple Viruses | 1 in force | to Aug 2030 |
| Cell Culture Methods and Devices Utilizing Gas Permeable Materials | 1 in force | to Jun 2027 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,697,443 | Cell Culture Methods and Devices Utilizing Gas Permeable Materials In force · High confidence | In force | High confidence | |
| US 9,732,317 | Highly Efficient Gas Permeable Devices and Methods for Culturing Cells In force · High confidence | In force | High confidence | |
| US 12,264,332 | Highly Efficient Gas Permeable Devices and Methods for Culturing Cells In force · High confidence | In force | High confidence | |
| US 9,963,677 | Generation of CTL Lines with Specificity Against Multiple Tumor Antigens or Multiple Viruses In force · High confidence | In force | High confidence | |
| US 10,533,156 | Methods of Cell Culture for Adoptive Cell Therapy In force · High confidence | In force | High confidence | |
| US 11,268,066 | Methods of Cell Culture for Adoptive Cell Therapy In force · High confidence | In force | High confidence | |
| US 11,999,969 | Methods of Cell Culture for Adoptive Cell Therapy In force · High confidence | In force | High confidence | |
| US 12,454,667 | Methods of Cell Culture for Adoptive Cell Therapy In force · High confidence | In force | High confidence | |
| US 11,821,002 | Methods of Cell Culture for Adoptive Cell Therapy In force · High confidence | In force | High confidence | |
| US 8,518,692 | Gas Permeable Cell Culture Device and Method of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 6 patents in force now held by others · 8 patents ended · 9 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.